April 19, 2022 at 6:16 pm
Aytu BioPharma (AYTU) Rises and Falls on News
Early today, Aytu BioPharma announced Fast Track Designation to AR101 for the treatment of Vascular Ehlers-Danlos Syndrome. As the news released, the stock surged around 25%. But, the stock fell throughout the day, and closed at $0.80, down 9.38%. Aytu BioPharma is a pharmaceutical company focused on developing and commercializing novel therapeutics and is located… [Read More]